<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01763710</url>
  </required_header>
  <id_info>
    <org_study_id>ONCOSUR-2012-01</org_study_id>
    <nct_id>NCT01763710</nct_id>
  </id_info>
  <brief_title>Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer</brief_title>
  <acronym>neurabrax</acronym>
  <official_title>Neurotoxicity Characterization Phase II Randomized Study of Nab-paclitaxel Versus Conventional Paclitaxel as First-line Therapy of Metastatic HER2-negative Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación Oncosur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación Oncosur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nanomedicines are currently being developed in the treatment of cancer due to their
      pharmacological advantages over traditional formulations; they provide a shorter infusion
      time and lower risks of hypersensitivity reactions associated with commonly used solvents.

      Nab-paclitaxel is a nanoparticle albumin-bound particle form of paclitaxel that is thought to
      exploit natural albumin pathways to enhance the selective uptake and accumulation of
      paclitaxel at the site of the tumour, thus reducing its diffusion to normal tissues.

      Nab-paclitaxel has been approved for the treatment of metastatic breast cancer patients who
      have failed first-line treatment for metastatic disease and for whom standard,
      anthracycline-containing therapy is not indicated.

      SPARC is a cysteine rich acid protein that is overexpressed in a broad proportion of solid
      tumours. Expression of this protein could sensitize tumour cells to antitumor activity of
      Nab-paclitaxel, due to its union through albumin-binding to this protein.

      First-line clinical trials have been developed with different Nab-paclitaxel regimens and
      also in combination with different chemotherapies and trastuzumab, showing a high level of
      efficacy.

      Toxicity profile of Nab-paclitaxel is well characterized with significantly less
      haematological toxicities compared with conventional paclitaxel.

      Nab-paclitaxel derived grade III neuropathy is short-lasting and more reversible than
      conventional paclitaxel-derived neuropathy, probably due to absence of Cremophor solvent, or
      due to paclitaxel itself.

      However there is still a lack of clinical and physiological characterisation of
      Nab-paclitaxel induced neuropathy.

      The current used tools for early detection and continuous evaluation of neurotoxicity are not
      optimal. Most used toxicity scales are limited, as they do not provide a detailed information
      of the severity of the neuropathy, its impact on quality of life, or physiopathology
      mechanisms.

      In addition, an inter-individual variability exists in terms of neurotoxicity predisposition
      when taxanes are used; it could be related to polymorphic differences in genes implicated in
      transport and metabolism of these drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TNS - Total Neuropathy Score</measure>
    <time_frame>Every 3 months up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the incidence of neuropathy induced by study treatment (conventional paclitaxel vs nab-paclitaxel)</measure>
    <time_frame>Every 3 weeks up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the electromyographic abnormalities and the correlation of these alterations with the assessment of the TNS scale and NCI-CTCAE (Common Toxicity Criteria for Adverse Effects) v4.0</measure>
    <time_frame>Every 12 weeks up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the predictive value of genetic variants (SNPs) for the development of neuropathy</measure>
    <time_frame>In the two weeks before start treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the clinical activity of both treatments (response rate, time to progression)</measure>
    <time_frame>Every 8-12 weeks up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine toxicity profile and safety of study treatments (NCI-CTCAE v4.0)</measure>
    <time_frame>Every 2 weeks up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine time to neurotoxicity onset</measure>
    <time_frame>Every 2 weeks up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine time to recovery from neurotoxicity</measure>
    <time_frame>Every 2 weeks up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine time to progression</measure>
    <time_frame>Every 8-12 weeks up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess quality of live (EORTC QLQ-C30 and EORTC QLQ-CIPN20)</measure>
    <time_frame>Every 4 weeks up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 80 mg/m2 days 1, 8 and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel 100 mg/m2 days 1, 8 and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel 150 mg/m2 days 1, 8 and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nab-paclitaxel 150 mg/m2 days 1 and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel 80 mg/m2</intervention_name>
    <description>Paclitaxel 80 mg/m2 days 1, 8 and 15</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel 100 mg/m2 days 1, 8 and 15</intervention_name>
    <description>Nab-paclitaxel 100 mg/m2 days 1, 8 and 15</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel 150 mg/m2 days 1, 8 and 15</intervention_name>
    <description>Nab-paclitaxel 150 mg/m2 days 1, 8 and 15</description>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel 150 mg/m2 days 1 and 15</intervention_name>
    <description>Nab-paclitaxel 150 mg/m2 days 1 and 15</description>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women with histologically or cytologically of stage IV breast cancer.

          2. Non-candidate patient to trastuzumab or lapatinib treatment as not presenting HER2
             oncogene amplification.

          3. Metastatic disease not previously treated with chemotherapy. It is allowed
             pre-treatment hormone with anti-target or bisphosphonates for advanced disease.

          4. Measurable or evaluable disease by RECIST criteria.

          5. Previous sensory neuropathy &lt;= grade 1, according to NCI-CTCAE criteria, due to any
             reason.

          6. Age&gt; 18 years.

          7. Performance status &lt;2 (ECOG).

          8. At least 12 months after the completion of adjuvant chemotherapy with taxanes to
             diagnosis of metastatic disease.

          9. Creatinine &lt;= 1.5mg/dL, AST (SGOT), ALT (SGPT) and alkaline phosphatase &lt;= 2.5 x ULN
             (hepatic metastases absent) in the 14 days prior to study entry.

         10. Hemoglobin&gt; 10g/dl, WBC&gt; 3000/mm3, platelets&gt; 100000/mm3 and bilirubin &lt;1.5 mg / dL in
             the 14 days prior to study entry.

         11. Women of childbearing potential with negative pregnancy test within 14 days prior to
             study treatment.

         12. Patients using adequate contraception throughout the entire duration of the study and
             until 4 weeks after completion of treatment.

         13. At least 4 weeks after radiotherapy or major surgery, with complete recovery.

         14. Life expectancy greater than 12 weeks.

         15. Patients who are able to meet the requirements of the protocol.

         16. Patients able to provide with two plasma samples (each sample 5cc) for analyzing
             polymorphisms.

         17. Written informed consent.

        Exclusion Criteria:

          1. Prior chemotherapy treatment for metastatic disease.

          2. Brain metastases.

          3. Concomitant treatment with hormone therapy or immunotherapy for breast cancer, or
             during the two weeks prior to inclusion in the study.

          4. Any concomitant medical or psychiatric illness including active infection.

          5. History of any malignancy other than breast cancer in the past 5 years except
             carcinoma or basal cell skin carcinoma or carcinoma in situ of cervix.

          6. Prior treatment with an investigational drug within the last 2 weeks.

          7. Known hypersensitivity to paclitaxel or Cremophor.

          8. Pregnant or breastfeeding.

          9. Have any acute, subacute or chronic peripheral nerve or spinal cord in grade, at the
             time of inclusion, greater than or equal to 2 (NCI CTCAE v4.0).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Ciruelos, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital 12 de Octubre, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noelia Martínez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hoapital Ramón y Cajal, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Carrión, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario del Sureste, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José A García Sáenz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico San Carlos, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María Echarri, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Severo Ochoa, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Blanca Cantos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta de hierro Majadahonda, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Coralía Bueno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Infanta Cristina, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel A Lara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Infanta Leonor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Santos Enrech, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Getafe, Servicio de Oncología Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan A Guerra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario de Fuenlabrada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Del Sureste</name>
      <address>
        <city>Arganda del Rey</city>
        <state>Madrid</state>
        <zip>28500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Leganés</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Cristina</name>
      <address>
        <city>Parla</city>
        <state>Madrid</state>
        <zip>28981</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2012</study_first_submitted>
  <study_first_submitted_qc>January 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2013</study_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Neurotoxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

